Protocols

Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study

⇨ Ascletis has in-licensed the Chinese market rights for Stockholm-based Medivir’s NS5B inhibitor for hep C. Terms weren’t disclosed but Hangzhou-based Ascletis gets another piece of the puzzle for a cocktail that can cure hep C, which it plans to hustle to regulators.

⇨ Cellectis $CLLS says they’ve dosed the first patient in their pioneering US human study of the first off-the-shelf CAR-T targeting CD123. The study of UCART123 is being carried out by investigators at MD Anderson in Houston.

⇨ We noted yesterday that WuXi used Ligand’s $LGND tech to develop the PD-1 that Arcus just in-licensed for the US and Europe. Today we learn that the Arcus deal will trigger a $2 million payment from WuXi to Ligand.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 19,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

BioNJ CEO Summit 2017